Over the past decade, we have witnessed a revolution in sequencing technologies that has had a profound impact on our understanding of genetics and genome biology. The next generation sequencing technology (NGS) has thus provided a great potential in the management and treatment of human health bridging to a new era of molecular pathology and personalized medicine. Eastern Biotech & Life Sciences proudly adds to its portfolio several NEW Cancer Genetic tests that will use the Next Generation Sequencing (NGS) technology. The cutting-edge technology utilizes a multi-target approach to detect mutation in specific genes & be able to detect various cancers.
BRCA1/2 Full Sequencing with Deletion & Duplication
BRCA1 and BRCA2 are tumor suppressor genes that have an essential role in both DNA repair and cell cycle control systems. Germline BRCA1 and BRCA2 mutations are implicated in 25-50% of hereditary breast cancer cases. The genetic test analyzes the BRCA1 and BRCA2 genes to identify any inherited changes (mutations) in them that can increase the risk for cancer.
GynPlus is a next generation sequencing panel that simultaneously analyzes 9 high-risk ovarian and uterine cancer susceptibility genes Genes on this panel include BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, and TP53. These nine genes are associated with four hereditary cancer syndromes hereditary breast and ovarian cancer (HBOC), Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome, all of which have published management guidelines. Identification of a mutation in one of these genes can help estimate cancer risk and guide treatment, screening, and/or prevention decisions for the patient.
BRCAplus™ is a next generation sequencing panel of 6 genes associated with breast cancer (BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53). These six genes are associated with five hereditary cancer syndromes (hereditary breast and ovarian cancer or HBOC, hereditary diffuse gastric cancer, hereditary breast and pancreatic cancer, Cowden syndrome, and Li-Fraumeni syndrome).
Colorectal Cancer Focus Panel
Colorectal Cancer Focus Panel examines 17 genes associated with an increased risk for hereditary colorectal cancer. Patients with a personal or family history suggestive of a hereditary colorectal cancer syndrome. Red flags for hereditary colorectal cancer could include onset of cancer prior to the age of 50 years, more than one primary cancer in a single person, and multiple affected people within a family. This test is appropriate for patients with both polyposis and nonpolyposis colorectal cancer. After consideration of a patient’s clinical and family history, this testing may be appropriate for some pediatric patients. (If there are specific genes that you do NOT want included, please indicate this on the test requisition form.) This test is designed to detect individuals with a germline pathogenic variant, and is not validated to detect mosaicism below the level of 20%. It should not be ordered on tumor tissue.
Comprehensive Cancer Panel
Comprehensive Cancer Panel is a next generation full gene sequencing hereditary cancer panel that simultaneously analyzes 122 genes associated with the most common hereditary cancers such as Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, Prostrate, Thyroid, and many more. About 10% of all cancer cases are due to hereditary cancer. The identification of the genetic cause of cancer in these patients allows the development of a personalized plan for clinical management for the affected patient and family members.